CV19 Lab Testing Dashboard powered by hc1
To support health care providers and public health agencies in responding to the COVID-19 pandemic,
hc1 is leading a coalition of 20K+ lab testing locations to power the CV19 Lab Testing Dashboard.

By cyoder® announced today that existing investor Health Cloud Capital has exercised its option to provide additional growth funding, bringing the company’s total Series B capital raise to $10 million. Elevate Ventures also participated in the round. The additional capital will fund continued expansion of several precision health initiatives underway at hc1, including solutions that combat the opioid crisis and optimize prescribing of other prescription drugs.

Subscribe to the blog
Previous Post How Healthcare CRM can Drive Profitability and Efficiencies in Toxicology Labs
Next Post Dives Deeper into Opioid Data, Precision Care